- Issuer ticker
-
MNPR
- Reported as of
-
02 Dec 2025
- Net transaction value
-
$0
Source evidence
Original filing metadata and source links for verification.
5 source fields
- SEC form
-
4
- Accepted by SEC
-
08 Dec 2025, 16:47:01 UTC
Reporting owner
1 detail
- Reporting owner signature
-
/s/ Quan Vu
Key filing fact
Quan Anh Vu filed Form 4 for Monopar Therapeutics (MNPR) on 08 Dec 2025.
Key facts
- This page summarizes Quan Anh Vu's Form 4 filing for Monopar Therapeutics (MNPR).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 08 Dec 2025, 16:47.
Change
- Previous filing in this sequence was filed on 05 Mar 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
Ownership activity is grounded in SEC Form 4 disclosures.
View source filing
Reporting Owners (1)
CIK 0001892297
Primary reporting owner
Vu Quan Anh
- Relationship
-
Chief Financial Officer
- Address
- 1000 SKOKIE BLVD SUITE 350, WILMETTE
- Signature
- /s/ Quan Vu
- Signature date
- 08 Dec 2025
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MNPR
transaction
Derivative
Stock Options
Award
- Transaction value
- $0
- Shares
- +7,135
- Change %
- Price
-
$0.000000
- Shares after
- 7,135
- Date
- 02 Dec 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 7,135
- Exercise price
- $75.94
- Footnotes
- F1
MNPR
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +9,826
- Change %
- Price
-
$0.000000
- Shares after
- 9,826
- Date
- 02 Dec 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 9,826
- Exercise price
- $0.000000
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Explanation of responses
2 footnotes